How effective is orforglipron compared to Wegovy?
Wegovy (injectable semaglutide) produces around 15% average weight loss at the standard 2.4 mg dose and over 20% weight loss at the higher approved 7.2 mg dose in Phase 3 trials. Orforglipron, an oral GLP-1 medicine still awaiting UK approval, has shown approximately 12–15% weight loss in clinical trials. While both reduce appetite via GLP-1 pathways and have similar gastrointestinal side effects, Wegovy currently delivers greater average weight loss and has stronger long-term evidence, whereas orforglipron’s main potential advantage is its tablet form.
This information has been fact-checked by Alessandro Grenci, Superintendent Pharmacist at medino.